BeOne Medicines
ONC
#777
Rank
HK$247.88 B
Marketcap
HK$2,389
Share price
-3.60%
Change (1 day)
36.24%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeOne Medicines (ONC)

EPS in 2026 (TTM): HK$37.61

According to BeOne Medicines's latest financial reports the company's current EPS (TTM) is HK$37.66. In 2025 the company made an earnings per share (EPS) of HK$21.37 an increase over its 2024 EPS that were of -HK$48.85.

EPS history for BeOne Medicines from 2015 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$37.6175.96%
2025HK$21.37-143.75%
2024-HK$48.85
2022-HK$152.6728.21%
2021-HK$119.08-19.96%
2020-HK$148.7820.81%
2019-HK$123.1631.52%
2018-HK$93.64417.57%
2017-HK$18.09-37.16%
2016-HK$28.79158.95%
2015-HK$11.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
OPKO Health
OPK
-HK$1.88-104.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-HK$7.44-119.75%๐Ÿ‡บ๐Ÿ‡ธ USA